Oncogenic K-Ras requires activation for enhanced activity

Oncogene

Volumn 33, Issue 4, 2014, Pages 532-535

  Huang, H ^a,b   Daniluk, J ^a,c   Liu, Y ^a   Chu, J ^a   Li, Z ^b   Ji, B ^d   Logsdon, C D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^d MAYO GRADUATE SCHOOL   (United States)

Author keywords

Cancer; Ras GTP

Indexed keywords

CANCER GROWTH FACTOR; CHOLECYSTOKININ; K RAS PROTEIN; PROSTAGLANDIN E2; KRAS2 PROTEIN, MOUSE; PROTEIN P21;

ACINAR CELL; ALLELE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CELL LYSATE; CONTROLLED STUDY; GENE ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; MOSAICISM; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROMOTER REGION; ANIMAL; CELL TRANSFORMATION; GENETICS; METABOLISM; MUTANT MOUSE STRAIN; MUTATION; NEOPLASM; ONCOGENE RAS; POLYACRYLAMIDE GEL ELECTROPHORESIS; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALIA;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENES, RAS; HUMANS; MICE; MICE, MUTANT STRAINS; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84897019899     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.619     Document Type: Article

References (21)

1. Spaargaren M, Bischoff JR, McCormick F. Signal transduction by Ras-like GTPases: a potential target for anticancer drugs. Gene Expr 1995; 4: 345-356.
2. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F et al. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 1997; 277: 333-338.
3. Koeffler HP, McCormick F, Denny C. Molecular mechanisms of cancer. West J Med 1991; 155: 505-514.
4. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761-774.
5. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008; 9: 517-531.
6. Yan L, McFaul C, Howes N, Leslie J, Lancaster G, Wong T et al. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 2005; 128: 2124-2130.
7. Lu X, Xu T, Qian J, Wen X, Wu D. Detecting K-ras and p53 gene mutation from stool and pancreatic juice for diagnosis of early pancreatic cancer. Chin Med J 2002; 115: 1632-1636.
8. Parsons BL, Meng F. K-RAS mutation in the screening, prognosis and treatment of cancer. Biomark Med 2009; 3: 757-769.
9. Yakubovskaya MS, Spiegelman V, Luo FC, Malaev S, Salnev A, Zborovskaya I et al. High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer. Int J Cancer 1995; 63: 810-814.
10. Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer cell 2003; 4: 111-120.
11. Carriere C, Young AL, Gunn JR, Longnecker DS, Korc M. Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. Biochem Biophys Res Commun 2009; 382: 561-565.
12. Daniluk J, Liu Y, Deng D, Chu J, Huang H, Gaiser S et al. An NF-kappaB pathwaymediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest 2012; 122: 1519-1528.
13. Tada M, Ohashi M, Shiratori Y, Okudaira T, Komatsu Y, Kawabe T et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology (Research Support, Non-U.S. Gov't) 1996; 110: 227-231.
14. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer cell 2003; 4: 437-450.
15. Ji B, Song J, Tsou L, Bi Y, Gaiser S, Mortensen R et al. Robust acinar cell transgene expression of CreErT via BAC recombineering. Genesis 2008; 46: 390-395.
16. Ardito CM, Gruner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK et al. EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis. Cancer cell 2012; 22: 304-317.
17. Siveke JT, Einwachter H, Sipos B, Lubeseder-Martellato C, Kloppel G, Schmid RM. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer cell 2007; 12: 266-279.
18. Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer cell 2007; 11: 291-302.
19. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243-3248.
20. Williams JA, Korc M, Dormer RL. Action of secretagogues on a new preparation of functionally intact, isolated pancreatic acini. Am J Physiol 1978; 235: 517-524.
21. de Rooij J, Bos JL. Minimal Ras-binding domain of Raf1 can be used as an activation- specific probe for Ras. Oncogene 1997; 14: 623-625.